These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38905044)

  • 1. Associations Between Free and Cued Selective Reminding Test and Cerebrospinal Fluid Biomarkers in Amnestic Mild Cognitive Impairment.
    Giuffrè GM; Quaranta D; Citro S; Morganti TG; Martellacci N; Vita MG; Rossini PM; Calabresi P; Marra C
    J Alzheimers Dis; 2024; 100(2):713-723. PubMed ID: 38905044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-Out-Test: A New Paradigm for Sorting the Wheat from the Chaff in Prodromal Alzheimer's Disease.
    Torrealba E; Garcia-Morales P; Cejudo JC; Diaz M; Rodriguez-Esparragon F; Fabre O; Mesa-Herrera F; Marin R; Sanchez-Garcia F; Rodriguez-Perez A; Gramunt N
    J Alzheimers Dis; 2019; 67(1):265-277. PubMed ID: 30530971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
    Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A
    J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Automatized FACEmemory® scoring is related to Alzheimer's disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort.
    Alegret M; Sotolongo-Grau O; de Antonio EE; Pérez-Cordón A; Orellana A; Espinosa A; Gil S; Jiménez D; Ortega G; Sanabria A; Roberto N; Hernández I; Rosende-Roca M; Tartari JP; Alarcon-Martin E; de Rojas I; Montrreal L; Morató X; Cano A; Rentz DM; Tárraga L; Ruiz A; Valero S; Marquié M; Boada M
    Alzheimers Res Ther; 2022 Mar; 14(1):43. PubMed ID: 35303916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial memory deficit profiles in patients with a cerebrospinal fluid Alzheimer's disease signature.
    Xie J; Gabelle A; Dorey A; Garnier-Crussard A; Perret-Liaudet A; Delphin-Combe F; Bathsavanis A; Dauphinot V; Lehmann S; Mercier B; Desestret V; Roullet-Solignac I; Vighetto A; Krolak-Salmon P
    J Alzheimers Dis; 2014; 41(4):1109-16. PubMed ID: 24762946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF Aβ
    Rizzi L; Maria Portal M; Batista CEA; Missiaggia L; Roriz-Cruz M
    Brain Res; 2018 Jan; 1678():27-31. PubMed ID: 29017912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease.
    Wagner M; Wolf S; Reischies FM; Daerr M; Wolfsgruber S; Jessen F; Popp J; Maier W; Hüll M; Frölich L; Hampel H; Perneczky R; Peters O; Jahn H; Luckhaus C; Gertz HJ; Schröder J; Pantel J; Lewczuk P; Kornhuber J; Wiltfang J
    Neurology; 2012 Feb; 78(6):379-86. PubMed ID: 22238414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construct validity of the Free and Cued Selective Reminding Test in older adults with memory complaints.
    Clerici F; Ghiretti R; Di Pucchio A; Pomati S; Cucumo V; Marcone A; Vanacore N; Mariani C; Cappa SF
    J Neuropsychol; 2017 Jun; 11(2):238-251. PubMed ID: 26560406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study.
    Reijs BLR; Ramakers IHGB; Köhler S; Teunissen CE; Koel-Simmelink M; Nathan PJ; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Vandenberghe R; Johannsen P; Blackwell A; Vanderstichele H; Verhey F; Visser PJ
    J Alzheimers Dis; 2017; 60(3):1119-1128. PubMed ID: 28984585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline.
    Eliassen CF; Reinvang I; Selnes P; Grambaite R; Fladby T; Hessen E
    Brain Behav; 2017 Sep; 7(9):e00776. PubMed ID: 28948074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Memory Alteration Test Is Correlated with Clinical, Cerebrospinal Fluid, and Brain Imaging Markers of Alzheimer Disease in Lima, Peru.
    Custodio N; Malaga M; Montesinos R; Chambergo-Michilot D; Baca F; Carbajal JC; Huilca JC; Herrera-Perez E; Lira D; Diaz MM; Lanata S
    Dement Geriatr Cogn Disord; 2023; 52(5-6):309-317. PubMed ID: 37827146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of Fully-Automated High-Throughput Plasma Biomarker Assays for Alzheimer's Disease in Amnestic Mild Cognitive Impairment Subjects.
    Giuffrè GM; Quaranta D; Vita MG; Costantini EM; Citro S; Carrozza C; De Ninno G; Calabresi P; Marra C
    J Prev Alzheimers Dis; 2024; 11(4):1073-1078. PubMed ID: 39044519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TMA-93 Validation by Alzheimer's Disease Biomarkers: A Comparison with the Free and Cued Selective Reminding Test on a Biobank Sample.
    Rodrigo-Herrero S; Luque-Tirado A; Méndez-Barrio C; García-Solís D; Bernal Sánchez-Arjona M; Oropesa-Ruiz JM; Maillet D; Franco-Macías E
    J Alzheimers Dis; 2021; 82(1):401-410. PubMed ID: 34024831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI.
    Vos SJ; van Rossum IA; Verhey F; Knol DL; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Frisoni GB; Froelich L; Nobili F; van der Flier W; Blennow K; Wolz R; Scheltens P; Visser PJ
    Neurology; 2013 Mar; 80(12):1124-32. PubMed ID: 23446677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Free and Cued Selective Reminding Test in Predicting [18F]Florbetaben PET Results in Mild Cognitive Impairment and Mild Dementia.
    Spallazzi M; Michelini G; Barocco F; Dieci F; Copelli S; Messa G; Scarlattei M; Pavesi G; Ruffini L; Caffarra P
    J Alzheimers Dis; 2020; 73(4):1647-1659. PubMed ID: 31958094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled sevoflurane may promote progression of amnestic mild cognitive impairment: a prospective, randomized parallel-group study.
    Liu Y; Pan N; Ma Y; Zhang S; Guo W; Li H; Zhou J; Liu G; Gao M
    Am J Med Sci; 2013 May; 345(5):355-60. PubMed ID: 23044653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker.
    Gleason CE; Norton D; Anderson ED; Wahoske M; Washington DT; Umucu E; Koscik RL; Dowling NM; Johnson SC; Carlsson CM; Asthana S;
    J Alzheimers Dis; 2018; 61(1):79-89. PubMed ID: 29125485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease.
    Marizzoni M; Ferrari C; Macis A; Jovicich J; Albani D; Babiloni C; Cavaliere L; Didic M; Forloni G; Galluzzi S; Hoffmann KT; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Pizzini F; Rossini PM; Salvatore M; Schönknecht P; Soricelli A; Del Percio C; Hensch T; Hegerl U; Tsolaki M; Visser PJ; Wiltfang J; Richardson JC; Bordet R; Blin O; Frisoni GB;
    J Alzheimers Dis; 2019; 69(1):49-58. PubMed ID: 30958351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can Subjective Memory Complaints Identify Aβ Positive and Aβ Negative Amnestic Mild Cognitive Impairment Patients?
    Mendes T; Cardoso S; Guerreiro M; Maroco J; Silva D; Alves L; Schmand B; Gerardo B; Lima M; Santana I; de Mendonça A
    J Alzheimers Dis; 2019; 70(4):1103-1111. PubMed ID: 31306132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.